does semaglutide affect vision A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no New study links Ozempic to

Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 17.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access 169.00 per year only 14.08 per issue Learn more Rent or buy this article Prices vary by article type from$1.95 to$39.95 Learn more Prices may be subject to local taxes which are calculated during checkout doi: Related Articles Blood tests for Alzheimers disease could reshape research and care The TREM2 agonistic antibody AL002 in early Alzheimers disease: a phase 2 randomized trial A minimally invasive dried blood spot biomarker test for the detection of Alzheimers disease pathology Read more research highlights selected by the Nature Medicine team Subjects Biomarkers Neurodegeneration Alzheimer's disease Latest on: Biomarkers Neurodegeneration An ECG biomarker for sudden cardiac death discovered with deep learning Article Passive heart-rate monitoring during smartphone use in everyday life Article Universal transcriptomic hallmarks of mammalian ageing and mortality Article Cell-type signatures of Alzheimers disease shared across population groups Article Dementia risk in middle-aged people linked to a blood protein Research Highlight The brain region that could provide a cognitive reservoir in old age Research Highlight Jobs Talent Recruitment Announcement at the College of Plant Science & Technology Gather Global Talents, Forge Great Achievements Wuhan, Hubei (CN) Huazhong Agricultural University (HZAU) Recruitment Announcement for High-Level Talent at the Center for Agricultural Microbiology Join HZAU's global faculty team to advance research with competitive benefits

By simultaneously aiming at GLP-1, GIP, and glucagon receptors, these drugs, such as retatrutide, deliver significantly greater efficacy than current therapies, expanding the addressable patient base

Table 1

The primary difference lies in their mechanism of action

Our focus remains on FDA-reviewed medications, which guarantee quality, safety, and effectiveness